Skip to main content

Table 5 Discordance in subtypes between the largest primary tumor (PT1) and the second tumor (PT2) assessed with immunohistochemistry and patients where therapy was added due to the discordance in specimens with ipsilateral multifocal primary breast cancer

From: Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer

  

PT2

 

Luminal A

Luminal B HER2-

Luminal B HER2 + 

Non-luminal HER2 + 

TNBC

Total

PT1

Luminal A

-

9 (2)a,c

5 (4)a,c

-

1 (1)a,c

15 (7)

Luminal B HER2-

21b

-

2 (2)a,c

-

-

23 (2)

Luminal B HER2 + 

4b

2b

-

1a

-

7

Non-luminal HER2 + 

1b,c

-

-

-

-

1

TNBC

1 (1)b,c

1 (1)b,c

-

-

-

2 (2)

Total

27 (1)

12 (3)

7 (6)

1

1 (1)

48 (11)

  1. Data are presented as number of patients with discordant subtypes (number of patients where therapy was added due to discordance in PT2)
  2. HER2 Human epidermal growth factor 2, TNBC Triple-negative breast cancer, PT Primary tumor
  3. amore aggressive molecular surrogate subtype change in PT2 compared to PT1
  4. bless aggressive molecular surrogate subtype change in PT2 compared to PT1
  5. cpatients with potential therapy changes
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us